Botulinum toxin type A for the treatment of provoked vestibulodynia: An open-label, pilot study

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 51, Issue 6, 2006, Pages 467-470

  Dykstra, Dennis D ^a   Presthus, James ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NONE

Author keywords

Botulinum A toxin; Pelvic pain; Provoked vestibulodynia; Vulvar diseases

Indexed keywords

BOTULINUM TOXIN A;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; FEMALE; HUMAN; INFLAMMATION; NOCICEPTION; OPEN STUDY; PAIN ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PROVOKED VESTIBULODYNIA; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT OUTCOME; VULVODYNIA;

ADULT; BOTULINUM TOXIN TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; NEUROTOXINS; PAIN; PILOT PROJECTS; VULVAR DISEASES;

EID: 33745198231     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Moyal-Barracco M, Lynch PJ: 2003 ISSVD terminology and classification of vulvodynia: A historical perspective. J Reprod Med 2004;49:772-777
2. National Institutes of Health: Vulvodynia Workshop: Towards Understanding a Pain Syndrome. Proceedings of NIH Vulvodynia Workshop, Bethesda, 2003
3. Harlow BL, Stewart EG: A population-based assessment of chronic unexplained vulvar pain: Have we underestimated the prevalence of vulvodynia? J Am Med Womens Assoc 2003;58:82-88
4. Bohm-Starke N, Hilliges M, Blomgren B, et al: Increased blood flow and erythema in the posterior vestibular mucosa in vulvar vestibulitis. Gynecol Obstet Invest 2001;98:1067-1074
5. Bohm-Starke N, Hilliges M, Falconer C, et al: Increased intraepithelial innervation in women with vulvar vestibulitis syndrome. Gynecol Obstet Invest 1998;46:256-260
6. Bohm-Starke N, Hilliges M, Brodda-Jansen G, et al: Psychophysical evidence of nociceptor sensitization in vulvar vestibulitis syndrome. Pain 2001;94:177-183
7. Glazer HI, Rodke G, Swencionis C, et al: Treatment of vulvar vestibulitis syndrome with electromyographic biofeedback of pelvic floor musculature. J Reprod Med 1995;40:283-290
8. Marinoff SC: Vulvar vestibulitis syndrome. Dermatol Clin 1992;10:435-444
9. Peckham BM, Maki DG, Patterson IJ, et al: Focal vulvitis: A characteristic syndrome and cause of dyspareunia: Features, natural history and management. Am J Obstet Gynecol 1968;154:855-864
10. Brin M, Vapnek JM: Treatment of vaginismus with botulinum toxin injections. Lancet 1997;349:252-253
11. Shafik A, El-Sibai O: Vaginismus: Results of treatment with botulinum toxin. J Obstet Gynaecol 2000;20:300-302
12. Ghazizadeh S, Nikzad M: Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol 2004;104:922-925
13. Aoki KR: Immunologic and other properties of therapeutic botulinum toxin serotypes. In Scientific and Therapeutic Aspects of Botulinum Toxin. Edited by M Brin, M Hallet, J Jankovic. Philadelphia, Lippincott Williams & Wilkins, 2002, pp 103-113
14. Montecucco C, Schaivo G, Rosseto O: The mechanism of action of tetanus and botulinum neurotoxins Arch Toxicol (suppl) 1996;18:342-354
15. Brin MF, Fahn S, Moskowitz C, et al: Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987;2:237-254
16. Wheller AH, Goolkasian P, Gretz SS, et al: A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998;23:1662-1667
17. Lang AM: A preliminary comparison of the efficacy and tolerability of botulinum toxin serotypes A and B in the treatment of myofascial pain syndrome: A retrospective, openlabel chart review. Clin Ther 2003;25:2268-2278
18. Binder WJ, Brin MF, Blitzer A, et al: Botulinum toxin type A (Botox) for treatment of migraine. Dis Mon 2002;48:323-335
19. Aoki KR, Cui M: Mechanisms of the antinociceptive effect of subcutaneous Botox: Inhibition of peripheral and central nociceptive processing. Cephalalgia 2003;23:649
20. Prukiss J, Welch M, Doward S, et al: Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: Involvement of two distinct mechanisms. Biochem Pharmacol 2000;59:1403-1406
21. Welch MJ, Purkiss JK, Foster KA: Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000;38:245-258
22. Durham PL, Cady R: Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: Implications for migraine therapy. Headache 2004;44:35-42
23. First ER: Application of botulinum toxin to the management of neurogenic inflammatory disorders, US patent number 6063768, 1996
24. Cui M, Khanijou S, Rubino J, et al: Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107:125-133